creased breast cancer incidence, [4] [5] [6] [7] [8] [9] preliminary analyses found fewer breast cancers in women in the CEE group, prompting a detailed updated analysis of breast cancer incidence and mammographic reports. The completed trial results reported herein include all events occurring prior to the stopping of the intervention and unblinding. Biologically plausible explanations for the possibility of decreased incidence of breast cancer with CEE are considered and examined in exploratory analyses, including interactions of treatment assignment with baseline risk factors.
METHODS
The WHI Estrogen-Alone trial enrolled 10 739 postmenopausal women with prior hysterectomy from 1993 through 1998 at 40 US clinical centers. 10 Women were recruited primarily by mass mailings and were eligible if they were aged 50 to 79 years at study entry, postmenopausal, and likely to reside in the same area for 3 years. Special attempts were made to recruit minority women in an effort to study the effects of hormone therapy in a cohort that reflected the ethnicity/racial diversity of postmenopausal women aged 50 to 79 years in the US population.
Individual women classified themselves regarding their race/ethnicity. The protocol and consent forms were reviewed and approved by the institutional review boards at each participating clinical center. Each woman provided written informed consent. The study exclusions included prior incidence of breast cancer and medical conditions likely to result in death within 3 years. Menopausal hormone use at screening required a 3-month washout before enrollment. All women had a baseline mammography screening and a clinical breast examination; suspicious findings required clearance before study entry. Breast cancer risk was assessed by interview and standardized questionnaires. Definitions of demographic and general health characteristics, and reproductive, medical, and family history, including hormone use, have been published. 10 Ovarian preservation was defined as no selfreport of bilateral oophorectomy.
Women were randomly assigned to 0.625 mg of CEE (Premarin, Wyeth, Collegeville, Pa) or an identicalappearing placebo. Randomization was carried out using a database distributed by the WHI clinical coordinating center; study pill bottles had unique bar codes and computer-based selection to ensure double-blinded dispensing. Study medication was discontinued for development of breast cancer, deep vein thrombosis or pulmonary emboli, malignant melanoma, level of triglycerides higher than 1000 mg/dL (Ͼ11.3 mmol/L), or use of tamoxifen, raloxifene, or any nonstudy estrogen, progestin, or androgen.
Follow-up Procedures
Participants were contacted 6 weeks after study entry to assess symptoms and promote adherence, at 6-month intervals to assess clinical outcomes, and annually for clinic visits. Study medications were withheld until completion of required annual mammography screenings and breast examinations. Initial outcomes were ascertained by selfadministered questionnaires. Breast cancer outcomes were confirmed by local clinic physician adjudicator review of medical records and pathology reports. Cases were then adjudicated at the clinical coordinating center using the Surveillance, Epidemiology, and End Results coding system. 11 Total breast cancers included the first of either invasive or in situ breast cancer.
Mammographic reports were obtained and reviewed locally at the clinical centers and coded for radiologist recommendation (negative, benign finding/negative, short interval follow-up suggested, suspicious abnormality, and highly suggestive of malignancy). Mammograms with suggested short interval follow-up and those with suspicious or highly suggestive findings were considered abnormal, with the latter 2 categories requiring clearance before dispensing ongoing study medication. Medical decisions regarding workup of breast findings were directed primarily by community physicians.
Study Termination
The sample size was based on hypothesized effects of estrogen on coronary heart disease after a proposed 9 years of follow-up. For monitoring purposes, a global index of benefit and risk was defined as time to the first event among coronary heart disease, invasive breast cancer, stroke, colorectal cancer, pulmonary embolus, hip fracture, and death from other causes. The National Institutes of Health stopped the trial earlier than planned because an increased risk of stroke in healthy women was considered unacceptable in the absence of a reduction in risk of coronary heart disease. At that time, 218 adjudicated invasive breast cancers were described and the in situ breast cancers had not been quantified. 3 The current study provides analyses of 237 invasive and 55 in situ centrally adjudicated breast cancers diagnosed by February 29, 2004 , the date participants were instructed to stop taking their study pills, resulting in a mean (SD) follow-up of 7.1 (1.6) years.
Statistical Analysis
Primary results were assessed with timeto-event methods and were based on the intention-to-treat principle. Hazard ratios (HRs) are based on Cox proportional hazards analyses stratified by age and randomization status in the WHI Dietary Modification trial. Nominal 95% confidence intervals (CIs) were used for inferences regarding invasive breast cancer because these were similar to CIs that acknowledge the sequential monitoring due to proximity of the stopping date to the planned study termination. In exploratory analyses, subgroup effects were tested as interactions between randomization assignment and selected baseline characteristics in Cox proportional hazards models that included both factors as main effects. P values for interaction were computed from likelihood ratio tests using a continuous variable for the baseline characteristic, wherever pos-sible. Nominal P values are presented, reflecting statistical significance without adjustment for multiple comparisons. Because 20 interactions with baseline characteristics were tested, chance alone would be expected to produce 1 significant interaction test at the .05 level of significance and 2 at the .10 level. Women with missing values for a given risk factor were omitted only from analyses requiring that variable.
The HRs by time since randomization were calculated from Cox proportional hazards models and tests for trends with time were obtained by incorporating a linear time interaction term. Kaplan-Meier plots describe breast cancer event rates over time. To assess the potential effect of nonadherence, adherence-adjusted analyses were conducted by censoring follow-up for a woman 6 months after she became nonadherent (defined as consuming Ͻ80% of study pills or starting nonstudy hormone therapy during the most recent study interval). Comparisons of selected breast cancer tumor characteristics were based on 2 , Fisher exact, or t tests. Statistical analyses were performed using SAS software, version 9.1.3 (SAS Institute Inc, Cary, NC).
RESULTS

Characteristics of Study Population
All women had prior hysterectomy and 41% had prior bilateral oophorectomy. Prior oophorectomy was somewhat less common in the CEE group. Women with bilateral oophorectomy differed from those with ovarian preservation but there were no substantial differences by treatment assignment.
Baseline breast cancer risk was comparable in the 2 study groups. Participants were at a moderate risk for their age, 12 with a mean (SD) 5-year Gail risk estimate 13 Fifty-two percent of all participants had never taken hormone therapy before study entry, less than 5% had ever taken estrogen combined with a progestin, and the remainder had taken estrogen only. Women with no prior hormone use differed from those with prior use in most variables shown in Table 2 , but there were no substantial differences by treatment assignment.
Only 5.2% of participants withdrew or were lost to follow-up and these losses were similar between the CEE group and the placebo group. 3 At study termination, 54% of participants were no longer adherent to study medication. Study pill discontinuation rates did not differ significantly by randomization assignment. Although women offered many reasons for discontinuation of study medication, the distribution of reasons was similar across both groups. The largest difference in reasons for stopping was in reported symptoms that are commonly associated with menopause or initiating menopausal hormones (24.5% for CEE vs 19.8% for placebo) with most of this difference attributed to breast symptoms (5.8% vs 1.6%). Use of nonstudy medications was reported by 8.4% of participants assigned to placebo and 5.3% of participants assigned to CEE.
Clinical Outcomes
In intention-to-treat analyses of all events (n=237 cases) occurring prior to intervention termination, nonsignificant reductions were observed for invasive breast cancer (HR, 0.80; 95% CI, 0.62-1.04; P = .09) and for total breast cancer (HR, 0.82; 95% CI, 0.65-1.04; P=.10) in women randomized to CEE only, while no effect on in situ disease was found (FIGURE 1). These results were not altered by adjusting for the small differences in the number of first-degree relatives with breast cancer or history of benign breast disease. There was no evidence of a trend with time in the invasive breast cancer HR (P=.29).
In further analyses, fewer breast cancers with localized disease were diagnosed in the CEE group than in the placebo group (HR, 0.69; 95% CI, 0.51-0.95), while the incidence of cancers of more advanced stage was comparable in the 2 groups (TABLE 3) . A similar reduction was found for ductal carcinomas (HR, 0.71; 95% CI, 0.52-0.99) but not for lobular disease. The interac- 
74).
In adherence-adjusted analyses that censored follow-up 6 months after a woman became nonadherent (FIGURE 2), a larger and significant reduction in the incidence of invasive breast cancer was observed in the CEE group compared with the placebo group (HR, 0.67; 95% CI, 0.47-0.97; P=.03).
Significant interactions were seen between treatment assignment (FIGURE 3) and estimated 5-year breast cancer risk (P=.01), history of benign breast disease (P=.005), and number of firstdegree relatives with breast cancer (P= .01). There was an apparent protective effect of CEE on breast cancer incidence observed in categories associated with lower risk in all 3 of these circumstances. No interaction was seen with oophorectomy status, body mass index (calculated as weight in kilograms divided by the height in meters squared), age at screening, menarche, first birth or menopause, prior oral contraceptive use, or nonsteroid antiinflammatory drug use. No significant interaction of CEE with prior estrogenonly use was observed; however, although the data were sparse, the in- teraction of CEE with prior use of combined E ϩ P was nominally significant (P =.03 ). The stratum-specific results suggested the possibility that an effect of CEE was concentrated in women without prior hormone exposure of any type (FIGURE 4) . No interactions were seen with duration or recency of prior hormone therapy use of any type. An analysis examining HRs by time since randomization revealed no significant trends overall or by prior hormone use.
Tumor Characteristics
Invasive breast cancers among women assigned to CEE were larger compared with those in women assigned to placebo (mean [SD], 1.8 cm [1.2] vs 1.5 cm [0.9]; P=.03) and a higher proportion tended to be node positive (35.5% vs 23.3%, respectively; P = .07) (TABLE 4).
Mammograms and Breast Biopsies
At baseline, detailed readings (other than cancer/no cancer) were available for 9844 mammograms and the frequency of mammograms with abnormalities was closely comparable in the 2 study groups ( 
001).
Each year thereafter, the percentage of mammograms requiring follow-up was significantly higher in the CEE group resulting in a cumulative percentage of 36.2% in the CEE group and 28.1% in the placebo group (PϽ.001) over the course of the trial. This difference was concentrated in the category of recommended short interval follow-up. The number of reports of breast biopsy or aspiration was similar between the 2 groups at year 1 but from year 2 onward the number of such reports was higher in the CEE group each year (range of difference, 27-43) to total 198 more biopsies or aspirations over the study duration (Table 5) .
COMMENT
In the WHI Estrogen-Alone trial, invasive breast cancer incidence did not differ significantly between women randomized to 0.625 mg/d of CEE compared with placebo over an average 7.1 years of follow-up. Preliminary results suggesting a lower breast cancer incidence in women in the CEE group were regarded as surprising in relation to prior evidence 14 and warranted a more detailed analysis. In the completed trial database, the invasive breast cancer incidence did not differ significantly between the CEE group and the placebo group (HR, 0.80; 95% CI, 0.62-1.04). However, exploratory analyses suggested that CEE might decrease breast cancer incidence in certain subgroups. In contrast, the proportion of mammograms with abnormalities requiring follow-up was significantly increased in the CEE group in the first year and in each year thereafter.
Although substantial evidence indicates that breast cancer risk is increased by both reproductive factorswhich influence endogenous estrogen levels 15 -and exogenous estrogen combined with progestin therapy, the evidence regarding an effect of exogenous estrogen only on breast cancer risk has been mixed. [6] [7] [8] [9] [16] [17] [18] [19] The preponderance of older observational studies that reported a modest increase in breast cancer diagnoses with use of unopposed estrogen were largely uncontrolled for mammography screening 4, 6 and detection bias may have confounded results. However, even recent reports differ. In the Million Women Study 9 (a combined crosssectional and cohort analysis), there was an increase in breast cancers with shortterm estrogen alone use whereas another similarly sized observational study reported no increase in breast cancer with estrogen only 16 and neither did 2 other studies reported during this period. 17, 18 In fact, Kerlikowske et al 19 reported an 8% decrease (95% CI, −16% to 0%) in breast cancer incidence among women taking estrogen alone for more than 5 years compared with those not taking hormones in a large cohort of women seen in community-based mammography practices.
A conceptual model based solely on stimulation of breast cancer growth by estrogen addition and inhibition by estrogen reduction cannot explain available clinical and preclinical findings. 20 In preclinical models, breast cancer cells 21, 22 and breast cancer xenographs 23, 24 demonstrate apoptosis or tumor regression in response to lowdose estradiol after prior estrogen deprivation. In postmenopausal breast cancer patients, estrogen reduction with aromatase inhibitors 25 and estrogen Participants with less than 80% adherence to study medications were censored 6 months after their first episode of nonadherence. CEE indicates conjugated equine estrogens; CI, confidence interval; HR, hazard ratio.
blockade with selective estrogenreceptor modulators like tamoxifen, 25 and exogenous estrogen [24] [25] [26] [27] [28] have anticancer effects. In addition, withdrawal of hormone therapy 29 (tamoxifen), 30 selective estrogen-receptor modulators, or the aromatase inhibitor exemestane 31 can result in breast cancer regression. These data are consistent with breast cancer cells being susceptible to estrogen fluctuations either above or below that tolerated by normal breast glandular tissues.
In subgroup analyses, which require cautious interpretation, significant reductions were observed in ductal carcinomas (HR, 0.71; 95% CI, 0.52-0.99) but not lobular tumors, and in invasive breast cancers in women who were adherent to study medications (HR, 0.67; 95% CI, 0.47-0.97; P=.03). An effect of CEE on breast cancer was seen in some subgroups at lower risk (lower Gail risk estimate, no firstdegree relative with breast cancer, or absence of benign breast disease). Such findings suggest a stronger influence of CEE on breast cancer not linked to family history and/or those less likely to be associated with microcalcification, a mammography finding that often leads to recommendation for breast biopsy.
The observation of a lower breast cancer incidence with CEE relative to placebo in women with no prior hormone use but not in women with prior hormone use generates a hypothesis that subsequent or continued estrogen use would not reduce risk further because sensitive breast cancer cells already had exogenous estrogen exposure. In this regard, similar annual breast cancer incidence rates (between 0.26% and 0.29%) were seen in CEE indicates conjugated equine estrogens; CI, confidence interval. *Gail risk score incorporates age, history of benign breast disease (atypia status unknown in the Women's Health Initiative), age at menarche, age at first birth, race/ ethnicity, and numbers of mothers and sisters with breast cancer.
the 3 groups with prior or current estrogen use while a higher annual incidence rate (0.40%) was seen only in the women with no prior estrogen exposure who were randomized to placebo (Figure 4) . Alternatively, the subgroup with the higher incidence may have simply occurred by chance.
In the WHI E ϩ P trial, CEE combined with medroxyprogesterone acetate significantly increased mammograms with recommended short interval follow-up as well as those suspicious or highly suggestive of malignancy. 2 In the current trial, CEE alone increased mammograms with recommended short interval follow-up but not those with more suspicious findings. Variability in radiologist use of a recommendation for short interval follow-up as well as the relation of such findings to breast cancer risk is recognized. [32] [33] [34] Nonetheless, a mammogram with this recommendation in clinical practice requires a repeat mammography screening after 6 months 32-34 with associated emotional and economic costs. [35] [36] [37] [38] This finding should be included in discussions of risk and benefit of CEE use.
A total of 198 more biopsies without a cancer diagnosis were reported by women in the CEE group over the course of the trial. Only about 20% of biopsies in such a screened population would have proliferative breast disease, 39 a finding that is associated with a modest 2% or 3% risk of breast cancer in the next decade, 40 thus differential removal of precancerous lesions in the CEE group by biopsies cannot explain the study findings.
Combined hormone use increases mammogram breast density compared with placebo or estrogen alone. [41] [42] [43] Further studies are needed to define any mediating role for breast density change on the differences in mammogram findings seen in the 2 WHI hormone trials.
Observational studies regarding characteristics of breast cancers diagnosed while taking estrogen alone also have been mixed. 19, 44 In the current randomized trial, the finding of a reduced incidence of localized tumors with no in- 2 or Fisher exact test for categorical variables. ‡Applies to those with a known tumor size (n = 76 for CEE and n = 102 for placebo). §Test of association by using only known values of the characteristic. Test of association by using the percentage missing for the characteristic. ¶Applies to those with a known number of lymph nodes examined, including those with zero nodes examined (n = 103
for CEE and n = 130 for placebo). #Applies to those with a known number of positive lymph nodes examined (n = 93 for CEE and n = 120 for placebo).
crease in higher-stage disease rates is consistent with the modest increase in average tumor size seen in women assigned to CEE. A relative reduction in invasive ductal compared with lobular carcinomas also could contribute because the latter demonstrates lower sensitivity to mammography detection. 45, 46 Analyses indirectly exploring diagnostic delay by considering prior hormone use were not definitive and hence this also remains a potential contributor.
However, the relatively short breast cancer doubling time of about 150 days [47] [48] [49] and the continued divergence of the incidence curves through more than 6 years of follow-up argues against a masking hypothesis as a major influence. Further follow-up to provide additional data regarding long-term consequences of CEE exposure is ongoing.
A relatively consistent interaction of body mass index with menopausal hormones on breast cancer has been reported in observational studies with greater hormone effects in women with lower body mass index. 7, 8, 43, 50 Nonetheless, no significant interaction of CEE and body mass index on breast cancer risk was seen in either the current Estrogen-Alone trial or in the WHI combined E ϩ P trial. 2 Regarding differences in findings between the E ϩ P and Estrogen-Alone trials, the study cohorts differed by uterine status (ie, all estrogen-alone par- Abbreviations: CEE, conjugated equine estrogens; NA, not applicable. *Data are presented as number (percentage) unless otherwise indicated. †PϽ.001 for comparison of frequency of abnormal mammogram (short interval follow-up suggested, suspicious abnormality, highly suggestive of malignancy) in the CEE group compared with the placebo group. ‡PϽ.01 for comparison of frequency of abnormal mammogram (short interval follow-up suggested, suspicious abnormality, highly suggestive of malignancy) in the CEE group compared with the placebo group. §P = .02 for comparison of frequency of abnormal mammogram (short interval follow-up suggested, suspicious abnormality, highly suggestive of malignancy) in the CEE group compared with the placebo group.
ticipants had a prior hysterectomy) and by a large number of other baseline characteristics. 51 Nonetheless, the mean 5-year Gail breast cancer risk estimates were similar (1.6% in the Estrogen-Alone trial and 1.5% in the E ϩ P trial) and annualized rates of invasive breast cancer were similar for the placebo groups in the 2 trials (0.34% in Estrogen-Alone trial and 0.33% in E ϩ P trial). Thus, cross-study differences in the study cohorts do not explain the differences in breast cancer effects seen and the results strongly suggest a role for progestin in relation to increasing breast cancer risk.
In conclusion, CEE alone for 7.1 years does not increase breast cancer incidence in postmenopausal women with hysterectomy and may decrease the risk of early stage disease and ductal carcinomas. This result is in clear contrast to the WHI trial of CEE combined with medroxyprogesterone acetate in women with a uterus, which showed a significant increase in breast cancer incidence over a mean of 5.6 years of follow-up. 2 Both trials showed a substantial increase in the frequency of mammograms requiring follow-up from the first year onward. However, this increase was seen only for recommended short-interval follow-up mammograms in the Estrogen-Alone trial, whereas it applied also to those with suspicious abnormality or highly suggestive of malignancy in the E ϩ P trial. 2 Initiation of CEE alone in women after hysterectomy should continue to be based on careful consideration of potential risks and benefits for a given individual.
